Working Together to Find a Cure     Print Page | Close Window

Press Release

PlasmaTech Biopharmaceuticals To Present at OneMedForum Investor Conference in San Francisco

DALLAS and NEW YORK, Jan. 12, 2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting a business overview and update at the OneMedForum investor conference Monday, January 12, 2015, in San Francisco.  Details are as follows:

 

Event:


OneMedForum Investor Conference

Date: 


Monday, January 12, 2015

Time: 


9:20 am Pacific Time

Location:


Marriott Marquis Hotel, 780 Mission Street, San Francisco

 

A live webcast of the presentation will be available by tuning in to OneMedTV at the following web address:  www.onemedmarket.com.

About PlasmaTech Biopharmaceuticals, Inc.:  PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care.  Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue clinical trials and operations and to the risks detailed in PlasmaTech's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.

PlasmaTech News

Company and Media Contact:
Harrison Wehner
President & CFO
PlasmaTech Biopharmaceuticals, Inc.
(617) 981-6955

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-to-present-at-onemedforum-investor-conference-in-san-francisco-300019007.html